Filed - Glenmark

More documents

Recommendations

Info

Background History 29-year old company Went public on Indian bourses in 1999 Identity / Scope Integrated, operating in Research, Manufacturing & Marketing of Pharmaceuticals Business interests span formulations and bulk activities Global Footprint Financial Performance Market Capitalisation Headquartered in Mumbai, India Operates in over 80 countries About 42% of revenues in FY 2006 from outside India Results in FY 2006 (ending March 31, 2006): • Consolidated revenues of ~ $171 Mn • Consolidated Profit after Tax of ~ $20 Mn ~USD 1026 Mn (as at October 26, 2006) 1
Strategy and Business Units 2
Page 2 and 3: Disclaimer This presentation has be
Page 6 and 7: Strategic roadmap: Transform into a
Page 8 and 9: Research and Development 5
Page 10 and 11: Licensing Strategy Partner Selectio
Page 12 and 13: NCE Pipeline Lead Target Indication
Page 14 and 15: NCE Pipeline Lead Target Indication
Page 16 and 17: Generic Formulations 13
Page 18 and 19: USA - Generic Formulations Current
Page 20 and 21: Europe - Start-up phase Strategy &
Page 22 and 23: Latin America Going forward Exp
Page 24 and 25: India Formulations Current Status
Page 26 and 27: India Formulations Moving forward,
Page 28 and 29: Active Pharmaceutical Ingredients C
Page 30 and 31: Financials and Projections Performa
Page 32 and 33: Financials and Projections Mileston
Page 34 and 35: Summary 31
Page 36: Thank you 33

Filed - Glenmark

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?